South Boston, MA, United States of America

Jose F Ponte

This inventor holds 14 USPTO granted patents and 11 published patent applications, plus 2 CIPO patents and 6 EPO patents. Top assignees: Gitr, Inc., Debiopharm International, S.a., Immunogen, Inc.. Active years: 2010-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jose F Ponte. Retrieved from https://idiyas.com/inventor/jose-f-ponte

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 11)

% Patents Active = 57.1

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 4)

Average Co-Inventor Count = 4.0

ph-index = 7

Forward Citations = 447(Granted Patents)

Location History:

Quincy, MA (US) (2013 - 2014)
South Boston, MA (US) (2010 - 2015)
Weymouth, MA (US) (2016 - 2022)

Company Filing History:

Debiopharm International, S.a.

Merck Sharp + Dohme Corp.

Years Active: 2010-2025

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12239732 - Anti-CD37 immunoconjugate and anti-CD20 antibody combinations (2025-03-04),

2. 11395796 - Anti-CD37 immunoconjugate and anti-CD20 antibody combinations (2022-07-26),

3. 11033564 - Therapeutic combinations comprising anti-FOLR1 immunoconjugates (2021-06-15),

4. 10570209 - Methods for inducing or enhancing an immune response by administering agonistic glucocorticoid-induced TNFR-family-related receptor (GITR) antibodies (2020-02-25),

5. 10172875 - Therapeutic combinations comprising anti-FOLR1 immunoconjugates (2019-01-08),

6. 10030074 - Methods of inducing or enhancing an immune response in a subject having cancer by administering GITR antibodies (2018-07-24),

7. 9493572 - GITR antibodies and methods of inducing or enhancing an immune response (2016-11-15),

8. 9241992 - Combination therapies employing GITR binding molecules (2016-01-26),

9. 9028823 - Methods of inducing or enhancing an immune response in a subject by administering agonistic GITR binding antibodies (2015-05-12),

10. 8901281 - ILT3 binding molecules and uses therefor (2014-12-02),

11. 8591886 - Combination therapies employing GITR binding molecules (2013-11-26),

12. 8388967 - Methods for inducing or enhancing an immune response by administering agonistic GITR-binding antibodies (2013-03-05),

13. 7812135 - GITR-binding antibodies (2010-10-12),

14. 7777008 - ILT3 binding molecules and uses therefor (2010-08-17),

Title: The Innovative Contributions of Jose F Ponte

Introduction

Jose F Ponte is a notable inventor based in South Boston, MA (US). He has made significant contributions to the field of immunology, particularly in the development of immunoconjugates for cancer treatment. With a total of 14 patents to his name, Ponte's work has the potential to impact the lives of many patients.

Latest Patents

Among his latest patents are the methods for administering anti-CD37 immunoconjugates in combination with anti-CD20 antibodies. These methods involve administering an anti-CD37 immunoconjugate, such as IMGN529, alongside an anti-CD20 antibody to individuals in need, particularly cancer patients. This innovative approach aims to enhance the efficacy of cancer treatments by utilizing targeted therapies.

Career Highlights

Throughout his career, Jose F Ponte has worked with several prominent companies, including Gitr, Inc. and Immunogen, Inc. His experience in these organizations has allowed him to refine his expertise in the development of therapeutic solutions for cancer.

Collaborations

Ponte has collaborated with notable colleagues in the field, including Paul D Ponath and Michael Rosenzweig. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Jose F Ponte's innovative work in the field of immunology exemplifies the impact that dedicated inventors can have on medical science. His contributions continue to pave the way for new treatment options for cancer patients.

Profile summary based on public USPTO records.